Stockscreener 앱 받기
2.15
0.92%
-0.02
시간 외 거래:
1.90
-0.25
-11.63%
전일 마감가:
$2.17
열려 있는:
$2.24
하루 거래량:
18,077
Relative Volume:
1.00
시가총액:
$13.70M
수익:
$500.00K
순이익/손실:
$-9.78M
주가수익비율:
-1.3944
EPS:
-1.5419
순현금흐름:
$-8.10M
1주 성능:
-22.10%
1개월 성능:
-24.30%
6개월 성능:
-62.99%
1년 성능:
-74.16%
1일 변동 폭
$2.10
$2.38
1주일 범위
$1.71
$3.05
52주 변동 폭
$1.71
$9.50
Exicure Inc Stock (XCUR) Company Profile
명칭
Exicure Inc
전화
847-673-1707
주소
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.33 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.79 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.25 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.77 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.74 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-20 | 개시 | Guggenheim | Buy |
Exicure Inc 주식(XCUR)의 최신 뉴스
XCUR Q2 2022 Earnings: EPS Misses Estimates as Exicure Reports No Revenue and Continues R&D Focus - newsline.com
Exicure Inc. Q2 2022 Earnings: Significant EPS Miss Amidst No RevenueGAAP Earnings Report - newsline.com
Exicure receives Nasdaq notice for falling below $2.5M equity requirement, plans to regain compliance. - Pluang
Exicure receives Nasdaq notice for equity deficiency - Investing.com
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement - The Manila Times
Exicure receives Nasdaq notice for equity deficiency By Investing.com - Investing.com Canada
XCUR Q2 2022 Earnings: Wider-Than-Expected Loss on No RevenueAnalyst Drop Coverage - newsline.com
Exicure Inc stock (US30205M1027): biotech penny stock seeks direction after strategic shifts - AD HOC NEWS
XCUR Technical Analysis | Trend, Signals & Chart Patterns | EXICURE INC (NASDAQ:XCUR) - ChartMill
Exicure Regains Nasdaq Compliance After Late Quarterly Filing - The Globe and Mail
Exicure Announces Receipt Of Nasdaq Delinquency Notice And Filing Of Form 10-Q - TradingView
Exicure receives Nasdaq notice for delayed quarterly filing By Investing.com - Investing.com South Africa
Exicure receives Nasdaq notice for delayed quarterly filing - Investing.com
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - The Manila Times
Exicure faces Nasdaq noncompliance over late 10-Q, then files report - Stock Titan
Exicure receives Nasdaq notice for late 10-Q, files report and says compliance restored - TradingView
Exicure (XCUR) addresses Nasdaq delinquency after delayed Q1 2026 10-Q filing - Stock Titan
Exicure, Inc. Q1 2026 Financials: Strategic Alternatives, Going Concern Doubts, and Zero Revenue Reported - Minichart
XCUR Q2 2022 Earnings: EPS Misses Estimates Amid Operational ChallengesProfit Margin Analysis - The Legal Advocate
Exicure Q2 2022 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentEarnings Outlook Update - The Legal Advocate
Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Exicure (NASDAQ: XCUR) posts Q1 2026 loss and flags going concern, Nasdaq risks - Stock Titan
Exicure Deadline Alert - TMX Newsfile
XCUR Q2 2022 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueFinancial Health Score - newsline.com
Exicure Inc. (XCUR) Q2 2022 Earnings: Wider-than-Expected Loss, No Revenue, Shares Edge Higher - The Legal Advocate
Exicure (XCUR) Q2 2022 Earnings: Wider-Than-Expected Loss Fails to Deter InvestorsStock Idea Network - Newser
Exicure Inc. (XCUR) Slips 3.6% as Shares Test Support Near $2.53Stock Idea Hub - Newser
XCUR Q2 2022 Earnings: Wider-than-Expected Loss Highlights Challenges for Pre-Revenue Biotech - Newser
Exicure Inc stock (US30205M1027): micro-cap biotech restructures after Nasdaq delisting - AD HOC NEWS
Exicure delays quarterly filing, trims quarterly loss - TipRanks
Exicure (XCUR) delays Q1 2026 10-Q; prelim net loss $1.83M - Stock Titan
Exicure stock (US30205M1027): Filing highlights ongoing biotech focus - AD HOC NEWS
TradingKey - TradingKey
XCUR (Exicure) shares decline 3% after EPS miss of 35.6%, raising concerns over biotech's cash burn and growth prospects.Trending Social Stocks - Newser
The biggest catalyst for Exicure (XCUR) nobody is watching (-1.82%) 2026-05-11Open Trading Community - Newser
Number of shareholders of Exicure, Inc. – SWB:2H0 - TradingView
Exicure Shareholder Alert - TMX Newsfile
What Exicure (XCUR) does that its rivals cannot (+2.12%) 2026-05-08Investment Community Signals - newser.com
The real value proposition of Exicure (XCUR) stock (-0.29%) 2026-05-06Value Ideas - Newser
XCUR Exicure shares drop 4.67% after Q2 2022 loss per share comes in far wider than analyst estimates.Social Buzz Stocks - Newser
XCUR Exicure Inc. posts wider than projected Q1 2022 loss while its shares climb on positive investor sentiment. - UBND thành phố Hải Phòng
Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies - Quiver Quantitative
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - The Globe and Mail
Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100) - marketscreener.com
New Exicure pact targets Burixafor combos for sickle cell, leukemia - Stock Titan
Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100) - marketscreener.com
Exicure (XCUR) Stock: Next Week (Touches Low) 2026-04-20Crowd Risk Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Exicure Inc (XCUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Exicure Inc 주식 (XCUR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Exicure HiTron Inc. | 10% Owner |
Jan 16 '26 |
Sale |
4.50 |
734,747 |
3,306,362 |
1,857,314 |
| Exicure HiTron Inc. | 10% Owner |
Jan 07 '26 |
Sale |
4.50 |
741,272 |
3,335,724 |
2,592,061 |
| SANGSANGIN INVESTMENT & SECURI | 10% Owner |
Dec 08 '25 |
Sale |
8.71 |
433,332 |
3,774,322 |
0 |
2.60%
0.94%
자본화:
|
볼륨(24시간):